The AOP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM AOP market size from 2018–2030. The Report also covers current AOP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Acute Ocular Pain Market Outlook
Eye pain is a myriad of symptoms ranging from a sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from very simple refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. A feeling of discomfort or pain in the eye can be caused by a problem in the eye itself. It can also be caused by a problem involving any structures around the eye or referred pain from tissues with similar innervation as ocular tissues. Most ophthalmologic conditions producing ocular pains are associated with obvious ocular symptoms and signs like red-eye, photophobia, vision loss, or diplopia. Sometimes it poses a challenge to physicians when the pain is associated with a quiet eye or “white eye.”
Pain associated with surgery, injury, infection, or inflammation at the front of the eye is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.
Recently various drugs such as Dextenza, Inveltys, BromSite, and Lotemax have been approved to treat ocular inflammation and pain following ophthalmic surgery and cataract surgery. Dextenza is the first FDA-approved intracanalicular insert, a novel route of administration that delivers the drug to the eye’s surface without the need for eye drops. The drug is a preservative-free, resorbable hydrogel insert that delivers 0.4 mg of dexamethasone to treat postsurgical ocular inflammation and pain for up to 30 days with a single administration.
Key Findings
- The market size of Acute Ocular Pain in the 7MM was estimated to be USD 276.02 million in 2020, and it is estimated to grow at a Compound Annual Growth Rate (CAGR) of 8.93% for the study period (2018–2030).
- According to the estimates, the highest market size of Acute Ocular Pain (AOP) was found in the United States, followed by Germany in the year 2020.
- The market size of AOP in the EU5 was estimated to be USD 89.18 million in 2020, and it is estimated to grow at a Compound Annual Growth Rate (CAGR) of 7.80% for the study period (2018–2030).
- Among the EU5 countries, Germany had the highest market size of AOP with USD 22.13 million in 2020, while Spain had the lowest market size for AOP with USD 13.06 million in 2020.
- Dextenza, Inveltys, and Lotemax SM—already approved in the US market—are expected to enter the European and Japan market in 2023, 2024, and 2024, respectively.
“Currently NSAIDs, Steroids, and others (Antibiotics) are used to manage acute ocular pain. These therapies are further classified into monotherapies and combination therapies. In combination therapies, the combination of Antibiotics + Steroids, NSAIDS + Antibiotics + Steroids, and others (Antibiotics + NSAIDs; Steroids + NSAIDs) are prescribed by the physicians as off-label therapies to manage ocular pain.
Dextenza, Inveltys, and Lotemax SM are the recently approved drugs indicated for post-operative pain management of cataract surgery. All these three therapies were launched in the US market in 2019. The other upcoming therapies that are being investigated for pain management in the case of Cataract surgeries and Dry Eye Disease (DED) include, APP13007, Reproxalap, and Tivanisiran (SYL1001). Reproxalap and Tivanisiran (SYL1001) are the only upcoming therapies that will be targeting the DED patient pool, and hence will be competing with each other. In their clinical results, it was observed that the drugs were successfully able to manage pain in the case of DED.
Reproxalap is estimated to capture the largest market among the upcoming therapies because it will be targeting the overall patient pool of DED.”
The United States Market Outlook
This section provides the total AOP market size and market size by therapies in the United States.
EU-5 Market Outlook
The total AOP market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total AOP market size and market size by therapies in Japan are provided.
Request for sample pages @ Acute Ocular Pain Market Size
Table of contents
1. Key Insights
2. Report Introduction
3. Acute Ocular Pain (AOP) Market Overview at a Glance
3.1. Market Share (%) Distribution of Acute Ocular Pain (AOP) in 2018
3.2. Market Share (%) Distribution of Acute Ocular Pain (AOP) in 2030
4. Executive Summary of Acute Ocular Pain (AOP)
5. Acute Ocular Pain (AOP) Market: Future Perspective
6. Disease Background and Overview
6.1. Introduction
6.2. Eye: Components and Anatomy
6.3. Causes
6.3.1. Ocular trauma
6.3.2. Conjunctival or corneal foreign body
6.3.3. Recurrent corneal erosions (RCE)
6.3.4. Dry eyes
6.3.5. Microbial keratitis
6.3.6. Glaucoma
6.3.7. Episcleritis
6.3.8. Scleritis
6.3.9. Uveitis
6.3.10. Optic neuropathies
6.3.11. Eye pain in cranial nerve palsies
6.3.12.. Eye pain in ocular asthenopia
6.3.13. Eye pain in migraine
6.3.14. Eyelid, orbit, and ocular adnexa
6.3.15. Ocular surface, conjunctiva, and cornea
6.3.16. Retinal diseases
6.4. Diagnosis
6.4.1. History
6.4.2. Physical examination
6.4.3. Testing
6.5. Differential Diagnosis and Management
6.6. Treatment and Management
6.6.1. Local treatment
6.6.1.1. Topical Ophthalmic NSAIDs
6.6.1.2. Ophthalmic Corticosteroids
6.6.1.3. Cholinergic Antagonists
6.6.1.4. Topical Anesthetics
6.6.2. Allergy eye drops
6.6.3. Surgery
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Epidemiology Methodology
7.3. Total Cases of Several Eye Disorders in the 7MM
7.4. Total Cases of Acute Ocular Pain (AOP) in the 7MM
7.5. Epidemiology of Acute Ocular Pain (AOP)
7.6. The United States
7.6.1. Number of Cases of Several Eye disorders in the United States
7.6.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in the United States
7.7. EU5
7.7.1. Germany
7.7.1.1. Number of Cases of Several Eye Disorders in Germany
7.7.1.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Germany
7.7.2. France
7.7.2.1. Number of Cases of Several Eye Disorders in France
7.7.2.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in France
7.7.3. Italy
7.7.3.1. Number of Cases of Several Eye Disorders in Italy
7.7.3.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Italy
7.7.4. Spain
7.7.4.1. Number of Cases of Several Eye Disorders in Spain
7.7.4.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Spain
7.7.5. United Kingdom
7.7.5.1. Number of Cases of Eye Disorders in the UK
7.7.5.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in the UK
7.8. Japan
7.8.1. Number of Cases of Several Eye Disorders in Japan
7.8.2. Number of Cases of Acute Ocular Pain in Major Eye Disorders in Japan
8. Organizations contributing towards Acute Ocular Pain (AOP)
9. Patient Journey
10. Case Reports
11. Marketed Products
11.1. Key Cross
11.2. Dextenza (dexamethasone ophthalmic insert): Ocular Therapeutix
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Inveltys (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. BromSite (bromfenac ophthalmic solution): Sun Pharmaceutical
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Safety and Efficacy
11.4.4. Product Profile
11.5. Lotemax SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
11.5.1. Product Description
11.5.2. Regulatory Milestones
11.5.3. Safety and Efficacy
11.5.4. Product Profile
11.6. Prolensa (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb
11.6.1. Product Description
11.6.2. Regulatory Milestones
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Safety and Efficacy
11.6.6. Product Profile
12. Emerging Therapies
12.1. Key Cross
12.2. APP13007: Formosa Pharmaceuticals
12.2.1. Drug Description
12.2.2. Regulatory Milestones
12.2.3. Clinical Development
12.2.4. Clinical Trials Information
12.2.5. Safety and Efficacy
12.2.6. Product Profile
12.3. Reproxalap: Aldeyra Therapeutics
12.3.1. Drug Description
12.3.2. Regulatory Milestones
12.3.3. Clinical Development
12.3.4. Clinical Trials Information
12.3.5. Safety and Efficacy
12.3.6. Product Profile
12.4. Tivanisiran (SYL1001): Sylentis
12.4.1 Drug Description
12.4.2. Regulatory Milestones
12.4.3. Clinical Development
12.4.4. Clinical Trials Information
12.4.5. Safety and Efficacy
12.4.6. Product Profile
13. Acute Ocular Pain (AOP): Seven Major Market Analysis
13.1. Key Findings
13.2. Market Methodology
13.3. Market Size of Acute Ocular Pain (AOP) in the 7MM
13.4. Market Size of Acute Ocular Pain (AOP) by Therapies in the 7MM
13.5. Market Outlook
13.6. Attribute Analysis
13.7. Key Market Forecast Assumptions
13.8.United States Market Size
13.8.1. Total Market Size of Acute Ocular Pain (AOP) in the United States
13.8.2. Market Size of Acute Ocular Pain (AOP) by Therapies in the United States
13.9. EU-5 Market Size
13.9.1. Germany
13.9.1.1. Total Market size of Acute Ocular Pain (AOP) in Germany
13.9.1.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Germany
13.9.2. France
13.9.2.1. Total Market size of Acute Ocular Pain (AOP) in France
13.9.2.2. Market Size of Acute Ocular Pain (AOP) by Therapies in France
13.9.3. Italy
13.9.3.1. Total Market size of Acute Ocular Pain (AOP) in Italy
13.9.3.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Italy
13.9.4. Spain
13.9.4.1. Total Market size of Acute Ocular Pain (AOP) in Spain
13.9.4.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Spain
13.9.5. United Kingdom
13.9.5.1.Total Market size of Acute Ocular Pain (AOP) in the United Kingdom
13.9.5.2. Market Size of Acute Ocular Pain (AOP) by Therapies in the United Kingdom
13.10. Japan
13.10.1. Total Market size of Acute Ocular Pain (AOP) in Japan
13.10.2. Market Size of Acute Ocular Pain (AOP) by Therapies in Japan
14. KOL Views
15. Market Drivers
16. Market Barriers
17. SWOT Analysis
18. Unmet Needs
19. Appendix
19.1. Bibliography
19.2. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/